Review Article
Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?
Table 1
Summary of hazard ratio of men and women with esophageal cancer in clinical trials.
| Authors/reference #/year | N (%Men) | N (%women) | N (Women/Men)% | PFS HR (95% CI)
| OS HR (95% CI)
| Cox regression analysis | Death ratio HR (95% CI) |
| Robb W.B. et al. /[4]/2015 | 146/170 =85.9 | 24/170 =14.1 | 24/146 =16.4 | metastatic recurrence F/M Univariable 0.26(0.06-1.09) Multivariable 0·35 (0·08, 1·47) | - | locoregional recurrence Univariable F/M 0·68 (0·24, 1·90) | - |
| Zhao Y, et al. /[5]/2015 | 297/346 =85.8 | 49/346 =14.2 | 49/297 =16.5 | - | - | | Death M: 0.89(0.75-1.07) F:0.83(0.57-1.21) |
| Dutton S.J. et al. /[2]/2014 | 372/449 =82.9 | 77/449 =17.1 | 77/372 =20.7 | M 0.82 (0.67–1.01) F 0.70 (0.44–1.12) | - | | - |
| Oppedijk V. et al. /[7]/2014 | 298/374 =80 | 76/374 =20 | 76/298 =25.5 | M/F 1.12(0.67-1.87) | - | | - |
| Swisher S.G. et al. [8]/2010 | 141/157 =90 | 16/157 =10 | 16/141 =11.3 | - | M:1.0(0.5-1.7) F: 1.0 | | - |
| Crehange G. et al./[9]/2007 | 412/446 =92.4 | 34/446 =7.6 | 34/412 =8.3 | M/F1.4(0.8-2.45) | - | | - |
| Burmeister B.H. et al./[10]/2005 | 206/256 =80.5 | 50/256 =19.5 | 50/206 24.3
| PFS M 0.93(0.67-1.29) F 0.42(0.19-0.91) M/F:1.28(0.86-1.90) OS M/F 1.36(0.93-1.99) | | | |
|
|